India, Pune – The Insight Partners has released a comprehensive report titled “Fluorine-18 Market Share, Size, Trends, and Forecast by 2031.As the world pivots towards precision medicine and rapid disease detection, the Fluorine-18 market stands out for its crucial role in revolutionizing PET imaging and radiopharmaceuticals. Enhanced by breakthroughs in automated synthesis, rising investments in nuclear medicine, and the growing burden of chronic diseases, Fluorine-18 isotopes are set to reshape diagnostic landscapes globally. With patient-centric advancements moving from lab to clinical settings, the next decade promises transformative opportunities for both market leaders and emerging players.

Market Size, Share, Trends, Analysis, and Forecast (2031)

• The fluorine-18 market size is projected to reach US$ 2.53 billion by 2031 from US$ 1.85 billion in 2024. The market is expected to register a CAGR of 4.7% during 2025–2031.
• North America leads in market share due to robust nuclear medicine infrastructure and frequent PET usage.
• Asia Pacific expected to be the fastest-growing region, fueled by growing healthcare investments and increasing adoption of PET imaging in oncology.
• Europe showcases steady growth, buoyed by government healthcare initiatives and early adoption of cutting-edge imaging technologies.​
• Emerging markets in Latin America, Middle East, and Africa present untapped opportunities with rising healthcare modernization and regulatory support.
• Technological innovations, such as artificial intelligence integration in imaging, are accelerating adoption rates.
• Regulatory approvals for novel tracers and decentralized isotope production are broadening access and clinical utility.
• Partnerships, exclusive licensing agreements, and product launches are shaping competitive dynamics through global and regional collaborations.
• Hospitals remain the primary end-users, while diagnostic centers and research facilities drive adoption in specialized applications.​

Global and Regional Analysis

Global:

• The rising global incidence of cancer and neurological disorders is a primary demand driver.
• Integration with theranostic applications—the combination of diagnostics and therapy—opens avenues for next-generation care and monitoring.
• New synthesis modules and automation have simplified production, lowering costs and opening new market entry points.

Get a sample PDF of the report -https://www.theinsightpartners.com/sample/TIPRE00038973

Regional Breakdown:

• North America: Focused on advanced clinical research, regulatory innovation, and high PET imaging volumes.
• Europe: Driven by personalized medicine, increased clinical trials, and supportive government policies.
• Asia Pacific: Witnessing rapid infrastructure upgrades, expanding PET facilities, and strategic partnerships for technology transfer.​
• Middle East & Africa/Latin America: Growing diagnostic capabilities and healthcare investments, peripheral yet accelerating contributors to global market volume.

Updated Market News

• GE HealthCare’s launch of Flyrcado (flurpiridaz F 18) revolutionizes myocardial perfusion imaging, improving precision in cardiovascular assessments.​
• Lantheus Holdings and GE HealthCare signed an exclusive licensing deal for the prostate cancer imaging agent PYLARIFY in Japan, expanding access in Asia.​
• Recent FDA approvals for advanced F-18 tracers enhance diagnostic rates for prostate and cardiovascular conditions.
• Strategic moves by market leaders focus on exclusive partnerships, innovation in tracer yields, and decentralizing production to meet regional demand.​

Key Drivers Accelerating Market Growth

• Rising prevalence of cancer and neurological disorders worldwide.
• Technological advancements in PET imaging and automated tracer production.
• Government support and investment in nuclear medicine infrastructure.
• Regulatory approvals for new tracers enable broad clinical integration.
• Strong push towards personalized medicine and early disease detection.
• Strategic partnerships and licensing deals foster innovation and market penetration.​

Key Players

• Lantheus Medical Imaging Inc
• Siemens Healthineers AG
• GE HealthCare Technologies Inc
• Curium Pharma
• Blue Earth Diagnostics Limited
• Eli Lilly and Co
• IBA Radiopharma Solutions

Emerging Trends and Market Opportunities

• Growth in neuroimaging and theranostic applications for Fluorine-18 tracers.
• Integration of artificial intelligence in tracer imaging analysis.
• Expansion of automated tracer synthesis enhances scalability and cost-effectiveness.
• Personalized and precision medicine applications increasingly depend on advanced radiopharmaceuticals.​

Recent Industry Developments

• Licensing and regulatory approvals for new diagnostic tracers.
• Hospital-radiopharmaceutical company partnerships to transfer technology and knowledge.
• Increased investment in decentralizing isotope production, improving access and reducing costs.
• Novel tracer launches for enhanced diagnosis and therapy monitoring in oncology and cardiology.​

Conclusion

Fluorine-18 continues to redefine medical diagnostics—with its pivotal role in PET imaging, rising healthcare infrastructure investment, and continuous innovation in radiotracers. The decade ahead will witness broader adoption, increased competition, and swift advances in patient-centered diagnostic solutions. Industry leaders, paired with global collaborations, are steering the future for more effective disease detection and management.

Trending Related Reports

• Delay Condoms Market – Global Forecast by 2030
• High Potent Pharmaceuticals Product Market – Growth Analysis through 2030
• Prescription Drugs Market – Outlook by 2030
• Biopharmaceutical Contract Manufacturing Market  – Global Trends by 2030

About The Insight Partners

The Insight Partners is a global leader in market research, delivering comprehensive analysis and actionable insights across diverse industries. The company empowers decision-makers with data-driven intelligence to navigate evolving markets and accelerate growth.

Contact Us:

• Contact Person: Ankit Mathur
• E-mail: [email protected]

Phone: +1-646-491-9876

Also Available in :

 Korean | German | Japanese | French | Chinese | Italian | Spanish

Frequently Asked Questions

Q1: What is the estimated value of the Fluorine-18 market by 2031?
A: The fluorine-18 market size is projected to reach US$ 2.53 billion by 2031 from US$ 1.85 billion in 2024. The market is expected to register a CAGR of 4.7% during 2025–2031.

Q2: Who are the leading players in the Fluorine-18 market?
A: Key players include Lantheus Holdings, Siemens Healthineers, Advanced Accelerator Applications, GE HealthCare, Jubilant Pharma Limited, and others.​

Q3: Which region dominates the Fluorine-18 market?
A: North America remains the top region, while Asia Pacific is the fastest growing.​

Q4: What are the main drivers for Fluorine-18 market growth?
A: Rising cancer rates, technological advancement in PET imaging, and new regulatory approvals boost market growth.​

Q5: What are the latest industry developments for Fluorine-18?
A: FDA and European approvals for novel tracers, exclusive licensing deals, and automated production technologies are shaping market dynamics.​